Eine Studie zu Ustekinumab bei pädiatrischen Teilnehmern mit mäßig bis schwer aktivem Morbus Crohn (UNITI Jr)
Eine Phase-3-Studie zur Wirksamkeit, Sicherheit und Pharmakokinetik von Ustekinumab als offene intravenöse Induktionsbehandlung, gefolgt von einer randomisierten, doppelblinden subkutanen Erhaltungstherapie mit Ustekinumab bei pädiatrischen Teilnehmern mit mittelschwerem bis schwerem aktivem Morbus Crohn
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Study Contact
- Telefonnummer: 844-434-4210
- E-Mail: Participate-In-This-Study@its.jnj.com
Studienorte
-
-
-
Brussels, Belgien, 1200
- Cliniques Universitaires Saint Luc
-
Brussels, Belgien, 1020
- Universitair Kinderziekenhuis Koningin Fabiola
-
Ghent, Belgien, 9000
- UZ Gent
-
Jette, Belgien, 1090
- UZ Brussel
-
Leuven, Belgien, 3000
- UZ Leuven
-
-
-
-
-
Aachen, Deutschland, 52074
- Universitätsklinikum Aachen
-
Berlin, Deutschland, 13353
- Charite-Universitätsmedizin Berlin - Berlin
-
Essen, Deutschland, 45147
- Universitätsklinikum Essen
-
Hanover, Deutschland, 30625
- Medizinische Hochschule Hannover
-
Munich, Deutschland, 80337
- Dr. von Haunersches Kinderspital
-
Regensburg, Deutschland, 93049
- KUNO Klinik St. Hedwig
-
Ulm, Deutschland, 89075
- Universitätsklinikum Ulm
-
-
-
-
-
Be’er Ya‘aqov, Israel, 70300
- Yitzhak Shamir Medical Center
-
Haifa, Israel, 34362
- Carmel Medical Center
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
Petah Tikva, Israel, 4920235
- Schneider Children's Medical Center
-
-
-
-
-
Bunkyō City, Japan, 113 8431
- Juntendo University Hospital
-
Gunma, Japan, 371-0034
- Gunma University Hospital
-
Ikoma, Japan, 630-0293
- Kindai University Nara Hospital
-
Kurume, Japan, 830-0011
- Kurume University Hospital
-
Saitama Shi, Japan, 330-8777
- Saitama Childrens Medical Center
-
Sendai, Japan, 989-3126
- Miyagi Children's Hospital
-
Setagaya Ku, Japan, 157 8535
- National Center for Child Health and Development
-
Shimotsuke, Japan, 329-0498
- Jichi Medical University Hospital
-
Tsu, Japan, 514 8507
- Mie University Hospital
-
-
-
-
-
Gdansk, Polen, 80 803
- Szpital im. M. Kopernika
-
Krakow, Polen, 30 663
- Uniwersytecki Szpital Dzieciecy w Krakowie
-
Rzeszów, Polen, 35-302
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw, Polen, 04 501
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Polen, 04 730
- Instytut Pomnik Centrum Zdrowia Dziecka
-
-
-
-
-
Kazan', Russland, 420138
- Kazan State Medical University
-
Moscow, Russland, 119571
- Russian National Research Medical University named after N.I.Pirogov
-
Nizhny Novgorod, Russland, 603950
- Privolzhsky Research Medical University of Ministry of Health of Russian Federation
-
Yaroslavl, Russland, 150032
- Yaroslavl Regional Children's Clinical Hospital
-
-
-
-
-
Budapest, Ungarn, 1083
- Semmelweis Egyetem
-
Debrecen, Ungarn, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Miskolc, Ungarn, 3526
- Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
-
Nyíregyháza, Ungarn, 4400
- Szabolcs Szatmár Bereg Vármegyei Oktatókórház
-
Szeged, Ungarn, 6720
- Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
-
-
-
-
Delaware
-
Wilmington, Delaware, Vereinigte Staaten, 19803
- Nemours DuPont Hospital for Children
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Children's Center for Digestive Health Care
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic
-
-
New Jersey
-
Morristown, New Jersey, Vereinigte Staaten, 07962
- Morristown Memorial Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28207
- Levine Childrens at Atrium Health
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033
- Penn State Hershey Children's Hospital
-
-
Texas
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Cook Childrens Medical Center
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Pediatric Specialists Of Virginia
-
-
-
-
-
Birmingham, Vereinigtes Königreich, B4 6NH
- Birmingham Children's Hospital
-
Bristol, Vereinigtes Königreich, BS2 8BJ
- University Hospitals Bristol and Weston NHS Foundation Trust
-
Cambridge, Vereinigtes Königreich, CB2 0QQ
- Cambridge University Hospitals NHS Foundation Trust
-
Edinburgh, Vereinigtes Königreich, EH16 4TJ
- Royal Hospital for Children and Young People
-
London, Vereinigtes Königreich, E1 2AT
- Royal London Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Beschreibung
Einschlusskriterien:
- Haben Morbus Crohn oder fistulierenden Morbus Crohn mit aktiver Colitis, Ileitis oder Ileocolitis, die zu irgendeinem Zeitpunkt in der Vergangenheit durch Endoskopie und Histologie bestätigt wurden
- Muss einen mittelschweren bis schweren aktiven Morbus Crohn haben (definiert durch einen Ausgangswert des Pediatric Crohn's Disease Activity Index [PCDAI] von mehr als [>] 30); während des Screenings für diese Studie eine Ileokoloskopie mit Anzeichen eines aktiven Morbus Crohn haben, definiert als Vorhandensein von Ulzerationen (die gleich dem Simple Endoscopic Score for Morbus Crohn [SES-CD]-Score größer oder gleich [>=] 3 sind). Das Ileokoloskopie-Verfahren muss innerhalb von etwa 3 Wochen vor der Verabreichung der Studienintervention in Woche 0 (Induktionsphase) erfolgen. Eine Video-Ileokoloskopie, die innerhalb von 3 Monaten vor dem Besuch in Woche 0 (Einleitungsphase) aufgezeichnet wurde, kann im Falle eines erneuten Screenings eines Teilnehmers verwendet werden, der sich einer Ileokoloskopie unterzogen hat, aber das anfängliche Screening aus einem anderen Grund von Fall zu Fall nicht bestanden hat Rücksprache mit dem Träger. Wenn eine Ulzeration aufgrund einer Striktur oder einer unzureichenden Darmvorbereitung nicht beurteilt werden kann, kann stattdessen mindestens eines der folgenden Kriterien angewendet werden: ein anormales C-reaktives Protein (CRP) (> 0,3 Milligramm pro Deziliter [mg/dl] oder 3,0 Milligramm pro Liter [mg/L] beim Screening) oder; fäkales Calprotectin von >= 250 Milligramm pro Kilogramm [mg/kg] oder >= 250 Mikrogramm pro Gramm [mcg/g] beim Screening
- Bei enteraler Ernährung muss vor der Induktionswoche 0 (Woche I-0) mindestens 2 Wochen lang ein stabiles Regime eingehalten worden sein
- Frauen im gebärfähigen Alter müssen beim Screening und in Woche I-0 vor der Verabreichung der Studienintervention einen negativen hochempfindlichen Urin-Schwangerschaftstest haben
Ausschlusskriterien:
- Hat Komplikationen von Morbus Crohn wie symptomatische Strikturen oder Stenosen, Kurzdarmsyndrom oder andere Manifestationen, die voraussichtlich eine Operation erfordern, die die Verwendung des PCDAI zur Beurteilung des Ansprechens auf die Therapie ausschließen oder möglicherweise die Fähigkeit zur Beurteilung beeinträchtigen könnten Wirkung der Behandlung mit Ustekinumab
- Haben Sie eine Vorgeschichte von latenter oder aktiver granulomatöser Infektion, Histoplasmose oder Kokzidioidomykose oder hatten Sie vor dem Screening eine nicht-tuberkulöse mykobakterielle Infektion
- Vorhandensein oder Vorgeschichte einer bösartigen Erkrankung, einschließlich Vorliegen oder Vorgeschichte einer lymphoproliferativen Erkrankung, einschließlich Lymphom, oder Anzeichen und Symptome, die auf eine mögliche lymphoproliferative Erkrankung hindeuten, wie z. B. Lymphadenopathie ungewöhnlicher Größe oder Lokalisation (z. oder periaortalen Bereichen) und monoklonaler Gammopathie unbestimmter Bedeutung oder klinisch signifikanter Hepatomegalie oder Splenomegalie
- eine Vorgeschichte mit mittelschwerer oder schwerer fortschreitender oder unkontrollierter Leber- oder Niereninsuffizienz haben; oder signifikante kardiale, vaskuläre, pulmonale, gastrointestinale, endokrine, neurologische, hämatologische, psychiatrische (einschließlich Suizidalität) oder metabolische Störungen
- Erhielt innerhalb von 3 Monaten vor der geplanten ersten Dosis der Studienintervention eine Prüfintervention, einschließlich aller Prüfimpfstoffe, oder verwendete ein invasives Prüfmedizinprodukt oder ist derzeit in eine Prüfstudie eingeschrieben; Der Erhalt eines Prüfimpfstoffs gegen die Coronavirus-Krankheit 2019 (COVID-19) ist kein automatisches Ausschlusskriterium
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Offenes Ustekinumab intravenös (i.v.): Induktionsphase
Alle Teilnehmer erhalten eine einzelne IV-Verabreichung von Ustekinumab in der Induktionswoche 0 (I-0) basierend auf der Körperoberfläche (BSA) (Milligramm pro Quadratmeter [mg/m^2]) oder einer nach Gewicht abgestuften Induktionsdosis (Milligramm pro Kilogramm [mg/kg]).
|
Ustekinumab wird in der Induktionsphase intravenös und in der Erhaltungsphase subkutan verabreicht.
|
|
Experimental: Ustekinumab subkutan (sc) alle 8 Wochen (q8w): Erhaltungszeitraum
Die Teilnehmer erhalten in den Erhaltungswochen (Wochen M)-0, M-8, M-16, M-24 eine SC-Verabreichung von Ustekinumab q8w basierend auf BSA (mg/m^2) oder gewichtsgestufter Induktionsdosis (mg/kg). , M 32 und M-40 und passendes Placebo in den Wochen M-12 und M-36, um die Blindheit aufrechtzuerhalten.
|
Ustekinumab wird in der Induktionsphase intravenös und in der Erhaltungsphase subkutan verabreicht.
Passendes Placebo wird als SC-Injektion verabreicht.
|
|
Experimental: Ustekinumab SC alle 12 Wochen (q12w): Erhaltungszeitraum
Die Teilnehmer erhalten eine SC-Verabreichung von Ustekinumab q12w basierend auf BSA (mg/m^2) oder gewichtsabgestufter Induktionsdosis (mg/kg) in den Wochen M-0, M-12, M-24, M-36 und passendem Placebo um Wochen M-8, M-16, M-32 und M-40, um die Blindheit aufrechtzuerhalten.
|
Ustekinumab wird in der Induktionsphase intravenös und in der Erhaltungsphase subkutan verabreicht.
Passendes Placebo wird als SC-Injektion verabreicht.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
Zeitfenster: Induction Week 8 (Week I-8)
|
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations.
The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score =5.
For albumin level, the maximum score = 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Induction Week 8 (Week I-8)
|
|
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
Zeitfenster: Maintenance Week 44 (Study Week 52)
|
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations.
The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score= 5.
For albumin level, the maximum score= 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Zeitfenster: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with TEAEs were reported.
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE did not necessarily have a causal relationship with the intervention.
TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Zeitfenster: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with TESAEs was reported.
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE did not necessarily have a causal relationship with the intervention.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly.
TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
Zeitfenster: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
|
Number of participants with AEs leading to discontinuation of study intervention were reported.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
|
|
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
Zeitfenster: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE did not necessarily have a causal relationship with the intervention.
AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Zeitfenster: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported.
It included hemoglobin (Hb).
Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences.
Higher grades showed more severe abnormalities.
Only abnormalities where atleast one participant had data are reported.
Inc = increased, Dec= decreased.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Zeitfenster: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with abnormalities in clinical laboratory parameters were reported.
It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB).
Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences.
Higher grades showed more severe abnormalities.
Only abnormalities where at least one participant had data are reported.
Inc = increased, Dec= decreased.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Zeitfenster: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
Zeitfenster: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
|
Serum ustekinumab concentrations were reported.
|
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
Zeitfenster: Induction Week 6 (Week I-6)
|
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10.
The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations.
Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity.
Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90.
Higher score indicate greater severity.
The sPCDAI score was calculated only when >=3 of the 6 components were available.
|
Induction Week 6 (Week I-6)
|
|
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
Zeitfenster: Induction Week 8
|
Assessment of response in children with Crohn's disease was evaluated using the PCDAI.
Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations.
Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality).
For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
|
Induction Week 8
|
|
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
Zeitfenster: Induction Week 6
|
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10.
The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations.
Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity.
Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90.
Higher score indicate greater severity.
The sPCDAI score was only calculated when >=3 of the 6 components were available.
|
Induction Week 6
|
|
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
Zeitfenster: Maintenance Period Week 8 (Study Week 16)
|
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing.
Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum.
Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity.
Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
|
Maintenance Period Week 8 (Study Week 16)
|
|
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
Zeitfenster: Maintenance Week 8 (Study Week 16)
|
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations.
Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality).
For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10.
Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
|
Maintenance Week 8 (Study Week 16)
|
|
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
Zeitfenster: Maintenance Week 44 (Study Week 52)
|
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing.
Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum.
Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity.
Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
|
Maintenance Week 44 (Study Week 52)
|
|
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
Zeitfenster: Maintenance Week 44 (Study Week 52)
|
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations.
Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality).
For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10.
Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
|
Maintenance Week 44 (Study Week 52)
|
|
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Zeitfenster: Maintenance Period Week 44 (Study Week 52)
|
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations.
The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score= 5.
For albumin level, the maximum score= 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Maintenance Period Week 44 (Study Week 52)
|
|
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
Zeitfenster: Maintenance Week 44 (Study Week 52)
|
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations.
The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score= 5.
For albumin level, the maximum score= 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Maintenance Week 44 (Study Week 52)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Darmerkrankungen
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Gastroenteritis
- Entzündliche Darmerkrankungen
- Morbus Crohn
- Aminosäuren, Peptide und Proteine
- Proteine
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Ustekinumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CR108864
- 2019-004225-24 (EudraCT-Nummer)
- CNTO1275CRD3004 (Andere Kennung: Janssen Research & Development, LLC)
- 2023-504978-38-00 (Registrierungskennung: EUCT number)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .